Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zaltenibart · OMS-906

Other · developed by Omeros

Phase 2 Most advanced trial

OMER Developer

2 Registered trials

What is Zaltenibart?

Zaltenibart is an investigational drug studied in C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis, Paroxysmal Nocturnal Hemoglobinuria.

At a glance

Also known as: OMS-906
Drug type: Other
Therapy area: Hematology
Developer: Omeros Corporation (OMER)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 0SOY20O318

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06209736	Phase 2	C3 Glomerulopathy	Recruiting	OMER
NCT05972967	Phase 2	Paroxysmal Nocturnal Hemoglobinuria	Completed	OMER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C3 GlomerulopathyIdiopathic Immune Complex-Mediated GlomerulonephritisParoxysmal Nocturnal Hemoglobinuria

More from Omeros

Narsoplimab FDA approved OMS103HP Phase 3 OMS103HP-S Phase 3 OMS201 Phase 1/2 OMS643762 Phase 2

Sources

ClinicalTrials.gov NCT06209736

Updated Oct 3, 2026. Something wrong or missing? Report it on the OMER page.

Follow OMER, the company behind Zaltenibart

See OMER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OMER catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z